Sign In
Buy SAN
$12.47
+0.310 (+2.55%)
At Close: Jun 04, 2026
Santander Looks Cheap At 6.3x P/E And 0.65x Tangible Book Value
03:14pm, Thursday, 28'th Apr 2022
Santander Looks Cheap At 6.3x P/E And 0.65x Tangible Book Value
Press Release: Sanofi continues to deliver strong business EPS growth driven by higher sales and improved margins in Q1
05:30am, Thursday, 28'th Apr 2022 GlobeNewswire Inc.
Sanofi continues to deliver strong business EPS(1) growth driven by higher sales and improved margins in Q1
Communiqué de presse : Poursuite de la forte hausse du BNPA des activités portée par la croissance des ventes et des marges au T1
05:30am, Thursday, 28'th Apr 2022 GlobeNewswire Inc.
Poursuite de la forte hausse du BNPA des activités(1) portée par la croissance des ventes et des marges au T1 Paris, le 28 avril 2022
Banco Santander Central Hispano (SAN) Q1 2022 Earnings Call Transcript
05:30am, Wednesday, 27'th Apr 2022 The Motley Fool
SAN earnings call for the period ending March 31, 2022.
Sanofi: Information concerning the total number of voting rights and shares – March 2022
06:28pm, Tuesday, 26'th Apr 2022 GlobeNewswire Inc.
Information concerning the total number of voting rights and shares, provided pursuant to article L. 233-8 II of the Code de commerce (the French Commercial Code) and article 223-16 of the Règlement
Sanofi: Informations relatives au nombre de droits de vote et d'actions – MARS 2022
06:28pm, Tuesday, 26'th Apr 2022 GlobeNewswire Inc.
Informations relatives au nombre total de droits de vote et d’actions prévues par l’article L. 233-8 II du Code de commerce et l’article 223-16 du Règlement général de l’Autorité des Marc
Communiqué de presse : Sanofi s’associe à McLaren Racing pour accélérer l’excellence de son outil industriel
10:47am, Tuesday, 26'th Apr 2022 GlobeNewswire Inc.
Press Release: Sanofi teams up with McLaren Racing to accelerate industrial excellence
10:47am, Tuesday, 26'th Apr 2022 GlobeNewswire Inc.Banco Santander SA (SAN) CEO Jose Antonio Alvarez on Q1 2022 Results - Earnings Call Transcript
10:33am, Tuesday, 26'th Apr 2022
Banco Santander SA (NYSE:SAN ) Q1 2022 Earnings Conference Call April 26, 2022 4:00 AM ET Company Participants Jose Antonio Alvarez - CEO & Vice Chairman Jose Garcia-Cantera - Senior EVP & Group CFO C
Spain's Santander Q1 profit rises 58% compared to same period a year ago
01:09am, Tuesday, 26'th Apr 2022
Spain's Santander on Tuesday said its net profit in the first quarter rose 58% compared to the same period a year ago thanks to a recovery in Europe and a solid performance in South America.
Santander to close branches early as it transitions towards digital banking
09:25am, Thursday, 21'st Apr 2022
Santander UK will close most of its branches at 3 pm on weekdays as part of a shift towards digital banking. Branches will operate between 9.30 am and 3 pm on weekdays, and from 9 am to 12.30 pm on Sa
The recovery will be uneven in banking, Oliver Wyman's O'Kelly says
02:14am, Thursday, 21'st Apr 2022
Ronan O'Kelly, European head of corporate and institutional banking at Oliver Wyman, discusses its latest review of the banking sector.
Santander's East Midtown tower has new owner with modern vision
03:45pm, Sunday, 17'th Apr 2022
East Midtown, a favored location for hedge funds and small financial firms, will soon have a prestigious new location for them. After serving as Santander's New York headquarters since 1991, the 134,0
Communiqué de presse: Publication, dans le New England Journal of Medicine, des résultats positifs de phase I/II du rilzabrutinib dans le traitement de la thrombocytopénie immune
05:00am, Thursday, 14'th Apr 2022 GlobeNewswire Inc.
Publication, dans le New England Journal of Medicine, des résultats positifs de phase I/II du rilzabrutinib dans le traitement de la thrombocytopénie immune
Press Release: Positive Phase 1/2 study results of rilzabrutinib in people with immune thrombocytopenia published in The New England Journal of Medicine
05:00am, Thursday, 14'th Apr 2022 GlobeNewswire Inc.
Positive Phase 1/2 study results of rilzabrutinib in people with immune thrombocytopenia published in The New England Journal of Medicine
